Speciality Medicines Ltd. (SPML) Share Price Rises 9.90% to Rs 172
- September 11, 2026
- Posted by: Kunal Singla
- Category: News
Speciality Medicines Share Price is rising today after the stock moved to Rs 172 from Rs 156.5, a gain of 9.90%, with market capitalisation at Rs 137.5 crore. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. That makes the move relevant as an intraday share price rise rather than a story built on speculation. For readers tracking Speciality Medicines Share Price Today, the sharp change in price action matters because it comes alongside a compact valuation profile and a trading-sector backdrop that can be compared directly with peers. Univest data also places the move within the day’s range, which helps frame whether the stock is simply firm or extending its early strength. Investors watching Speciality Medicines Stock News should now focus on valuation context, sector positioning and the next verified update in price action.
Speciality Medicines Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 172 |
| Previous Close | Rs 156.5 |
| Today's Move | Rs 15.5 (+9.9%) |
| Open | Rs 165.5 |
| High | Rs 172.15 |
| Low | Rs 165.5 |
| Market Capitalisation | Rs 137.5 crore |
| Market Cap Category | Micro Cap |
Speciality Medicines Ltd. (SPML) rose to Rs 172 from the previous close of Rs 156.5, a move of Rs 15.5 or 9.9%. The stock opened at Rs 165.5, reached a high of Rs 172.15, recorded a low of Rs 165.5.
Speciality Medicines Share Price is higher by Rs 15.5, and the stock is trading at Rs 172 after opening at Rs 165.5. The move leaves the share price near the day’s high of Rs 172.15 and above the day’s low of Rs 165.5, showing a clear intraday price rise. Speciality Medicines Share Price Today also needs to be read against the previous close of Rs 156.5, which sets the day’s benchmark for the gain. According to latest Univest data, the price action is straightforward: the stock has moved up strongly, and the latest quote is close to the upper end of the day’s range. That is the main market takeaway from the share price update, without needing to infer any trigger. For readers following Speciality Medicines Stock News, the next step is to place this move alongside the company’s financial ratios and sector valuation.
Speciality Medicines Ltd. (SPML) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 137.5 crore |
| P/E Ratio | 10.55x |
| P/B Ratio | 1.93x |
| ROE | 37.85% |
| ROCE | 34.47% |
| EPS | Rs 14.83 |
| Book Value Per Share | Rs 81.03 |
| Dividend Yield | 0% |
Speciality Medicines Ltd. (SPML) fundamental metrics show P/E 10.55x, P/B 1.93x, ROE 37.85%, ROCE 34.47%. Read together, these ratios describe the company’s position rather than a recommendation.
Speciality Medicines Ltd. has a market capitalisation of Rs 137.5 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 10.55x, P/B at 1.93x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 37.85% and ROCE of 34.47%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 14.83, book value per share of Rs 81.03, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 23.2x, median ROE of 4.11%, median ROCE of 6.09%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Trading |
| Industry | Trading |
| Benchmark Scope | same industry |
| Company P/E Ratio | 10.55x |
| Benchmark Median P/E | 23.2x |
| Benchmark Average P/E | 105.56x |
| Benchmark P/E Range | 0.14x to 7,283.64x |
| Company P/B Ratio | 1.93x |
| Benchmark Median P/B | 1.39x |
| Company ROE | 37.85% |
| Benchmark Median ROE | 4.11% |
| Company ROCE | 34.47% |
| Benchmark Median ROCE | 6.09% |
| Company Market Capitalisation | Rs 137.5 crore |
| Benchmark Median Market Cap | Rs 53.22 crore |
Speciality Medicines Ltd. (SPML) operates in the Trading sector, within the Trading industry.
Speciality Medicines Ltd. (SPML) has a P/E ratio of 10.55x, which is below the benchmark median of 23.2x, a difference of -54.53%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Speciality Medicines Ltd. (SPML) has a ROE of 37.85%, which is above the benchmark median of 4.11%, a difference of +820.92%. Speciality Medicines Ltd. (SPML) has a ROCE of 34.47%, which is above the benchmark median of 6.09%, a difference of +466.01%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Adani Enterprises Ltd. | ADANIENT | 3,82,331.87 | 51.97 | 4.1 | 15.07 | 13.3 |
| Aegis Logistics Ltd. | AEGISLOG | 49,166.32 | 38.12 | 7.23 | 20.71 | 19.76 |
| ADITYA INFOTECH LIMITED | CPPLUS | 46,587.2 | 102.49 | 13.91 | 25.68 | 29.48 |
| Premier Energies Ltd. | PREMIERENE | 39,800.2 | 24.21 | 8.48 | 42.6 | 33.72 |
| Redington Ltd. | REDINGTON | 31,098.99 | 18.97 | 3.04 | 13.6 | 18.96 |
Speciality Medicines Ltd. (SPML) has a P/E ratio of 10.55x compared with the displayed peer median of 38.12x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 37.85% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 34.47% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Speciality Medicines Ltd. (SPML) has a market capitalisation of Rs 137.5 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Speciality Medicines
- Speciality Medicines Share Price is up 9.90% today, making it a clear intraday mover.
- The stock is trading close to the day’s high, which keeps Speciality Medicines Share Price in focus.
- P/E of 10.55 and P/B of 1.93 give the share price move a valuation context.
- ROE of 37.85% and ROCE of 34.47% are strong in the Trading sector benchmark.
- Speciality Medicines Stock News also stands out because no company-specific catalyst is established in the verified update.
About Speciality Medicines
Speciality Medicines Ltd. operates in the Trading sector and Trading industry. The latest Univest figures place Speciality Medicines Share Price within a valuation framework built on earnings, book value and return ratios rather than on a broad disclosure of operating segments.5 crore, EPS of Rs 14.83, book value of Rs 81.03, P/E of 10.55, P/B of 1.93, ROE of 37.85% and ROCE of 34.47%. Dividend yield is 0%, so the current profile is not defined by payout. As a Trading name, its position in the industry is best compared with the peers and benchmark metrics already visible in the article, which is how Univest keeps the discussion grounded in verified numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Speciality Medicines Share Price rising today?
Ans. Speciality Medicines Share Price is higher because it moved from Rs 156.5 to Rs 172, a gain of 9.90%. Univest data confirms the move itself, though no company-specific trigger has been identified.
What is Speciality Medicines Share Price Today?
Ans. Speciality Medicines Share Price Today is Rs 172. The stock opened at Rs 165.5 and touched a high of Rs 172.15, so the intraday move stayed close to the upper end of the day’s range.
What is the market capitalisation of Speciality Medicines?
Ans. Speciality Medicines has a market capitalisation of Rs 137.5 crore. That figure helps frame Speciality Medicines Share Price against its financial ratios and peer set, especially when compared with larger trading names in the sector.
How does Speciality Medicines compare with sector peers?
Ans. Speciality Medicines Share Price trades below peer P/E readings such as Adani Enterprises, Aegis Logistics and Aditya Infotech, while its ROE and ROCE are stronger than several names in the Trading peer list.
What are the key fundamentals behind Speciality Medicines Share Price?
Ans. Speciality Medicines Share Price is supported by EPS of Rs 14.83, book value of Rs 81.03, P/E of 10.55 and P/B of 1.93. Dividend yield is 0%, so payout is not part of the current profile.
Is Speciality Medicines a trading-sector stock?
Ans. Yes. Speciality Medicines belongs to the Trading sector and Trading industry. That sector context matters for Speciality Medicines Share Price because benchmark comparisons are drawn from the same industry group of 462 companies.
Where can I track Speciality Medicines Share Price live?
Ans. You can track Speciality Medicines Share Price live on Univest, along with valuation ratios, 52-week levels and market insights. That makes it easier to monitor the stock’s price action and sector context together.
Track Speciality Medicines Share Price on Univest
Use Speciality Medicines Ltd. (SPML) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Investors tracking Speciality Medicines Share Price can use Univest to follow the live share price, current market capitalisation, P/E, P/B, ROE, ROCE, EPS, book value and 52-week levels in one place. Speciality Medicines Share Price Today can also be monitored alongside Speciality Medicines Stock News and broader market insights. Univest keeps the stock view focused on verified price action, financial ratios and sector context.
